LONDON, United Kingdom — Novel Concepts Medical is proud to announce breakthrough results from its labs in Israel showing that its plant-based formula resulted in over 99% decrease in cell viability of colon cancer cells. The test was performed at one of the premier labs in Israel located in Ness Ziona’s science park. The lab results showed that after 48 hours of incubation, there was a decrease in cell viability by 99.29% in HT29 colon cancer cells. The conclusion of the test was that the formula “resulted in a strong decrease in cell viability in HT29 colon cancer cells.”
Novel Concepts Medical founder, Rachel Alkalay, PhD, said that the company will consider global collaborations in order to make it approachable for any person in the world.
Earlier this year, the company published a successful case study with a colon cancer patient. The study showed improvement with metastases in the patient’s liver and shrinkage of his tumor size after using our plant-based treatment. No side effects were reported related to the treatment.
Novel Concepts Medical and its founder have previously been recognized for their work in the field of plant-based treatment. The company received the “Most Pioneering Life Savings Treatments R&D Company – 2023 Middle East” award from Global Health & Pharma Magazine, and Dr. Alkalay won “One of the top 3 innovative and Creative Women Inventors for 2023” award in the FICPI’s World IP Day competition.
